Cornelius J. Mcginn, MD | Authors

Current Perspectives on Locally Advanced Pancreatic Cancer

November 01, 2000

This year, approximately 40% of the 28,300 patients diagnosed with pancreatic carcinoma in the United States will present with locally advanced disease. Radiotherapeutic approaches are often employed, as these patients

Radiosensitization by Gemcitabine

October 01, 1999

Gemcitabine is a potent radiosensitizer in both laboratory studies and in the clinic. Initial laboratory studies showed that gemcitabine radiosensitizes a wide variety of rodent and human tumor cells in culture. Maximum